NGM621抑制补体因子3治疗地图样萎缩:1期剂量递增研究结果
这项多中心、开放标签的1期研究纳入15例地图样萎缩患者,评估玻璃体腔注射NGM621的安全性和耐受性。单次递增剂量(2、7.5、15 mg)或多次剂量(15 mg,间隔4周)均未出现严重不良事件、药物相关不良事件或脉络膜新生血管,视力和病灶面积稳定,血清暴露呈剂量比例,未检出抗药抗体。
要点
- NGM621玻璃体腔注射 up to 15 mg 安全可耐受,无严重或药物相关不良事件。
- 治疗12周内未发生脉络膜新生血管,视力和地图样萎缩病灶面积稳定。
- 血清暴露呈剂量比例,各评估时间点均未检出抗药抗体。
核心结论
- NGM621玻璃体腔注射最高15 mg在地图样萎缩患者中安全且可耐受。
研究设计与样本
- 多中心、开放标签、单次和多次剂量1期研究,在美国4个中心纳入15例地图样萎缩患者。
主要发现
- 全部15例完成12周研究,无严重不良事件、无药物相关不良事件、双眼均未发生脉络膜新生血管。
- 所有队列至第12周平均视力和地图样萎缩病灶面积表现稳定。
- 药代动力学分析显示NGM621血清暴露呈剂量比例,各评估时间点未检出抗药抗体。
关键数值与推荐
- 入组患者地图样萎缩病灶面积≥2.5 mm²,研究眼最佳矫正视力4至54个字母(Snellen等效20/80至20/800),双眼无脉络膜新生血管病史。
- 单次递增剂量阶段剂量为2 mg、7.5 mg和15 mg;多次剂量阶段为15 mg间隔4周共2次,监测12周(85天)。
临床怎么用
- 该1期研究支持NGM621玻璃体腔注射最高15 mg在地图样萎缩中安全可耐受,需后续研究进一步验证疗效。
局限性
- 样本量小(15例)、开放标签、随访仅12周,不支持疗效结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and tolerability of single and multiple intravitreal injections of NGM621 in patients with geographic atrophy (GA) and to characterize the pharmacokinetics and immunogenic potential. DESIGN: Multicenter, open-label, single- and multiple-dose phase 1 study. METHODS: Fifteen patients enrolled at 4 sites in the United States. Participants had GA secondary to age-related macular degeneration, lesion size ≥2.5 mm2, best-corrected visual acuity of 4 to 54 letters (20/80 to 20/800 Snellen equivalent) in the study eye, and no history of choroidal neovascularization in either eye. Patients who met eligibility criteria were treated in a single ascending-dose phase (2 mg, 7.5 mg, and 15 mg) or received 2 doses of NGM621 (15 mg) 4 weeks apart in the multidose phase and were monitored for 12 weeks (85 days). Assessments included adverse events, best-corrected visual acuity, low-luminance visual acuity, vital signs, clinical laboratory evaluations, GA lesion area as measured by fundus autofluorescence, spectral domain optical coherence tomography, and pharmacokinetic, immunogenicity, and pharmacodynamic assessments. RESULTS: All 15 participants completed the 12-week study. There were no serious adverse events, no drug-related adverse events, and no choroidal neovascularization developed in either eye. Mean visual acuity and GA lesion area appeared stable through week 12 for all cohorts. Pharmacokinetic analyses indicated that NGM621 serum exposures appeared to be dose proportional, and no antidrug antibodies were identified at any of the evaluated time points. CONCLUSIONS: In this small, open-labeled, 12-week phase 1 study, NGM621 was safe and tolerable when administered intravitreally up to 15 mg.<END ABSTRACT>.
引用
- Wykoff CC, Hershberger V, Eichenbaum D, et al. Inhibition of Complement Factor 3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results. Am J Ophthalmol. 2021. PMID: 34509438. doi:10.1016/j.ajo.2021.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。